▎ 摘　　要

NOVELTY - Method for evaluating neuroprotective effect of a therapeutic agent on astrocyte resilience in an Alzheimer's animal model involves (a) measuring a cognitive resilience index through a cognitive behavioral experiment of an Alzheimer's animal model to which the therapeutic agent is administered, (b) analyzing the type and distribution of brain cells in the brain tissue of the animal model pre-treated for tissue clearing through a three-dimensional fluorescence microscope image, and (c) analyzing the type and distribution of brain cells in the brain tissue of the animal model pre-treated for tissue clearing through confocal microscopy images. USE - The method is useful for evaluating the neuroprotective effect of a therapeutic agent on astrocyte resilience in an Alzheimer's animal model. The pharmaceutical composition is useful for preventing or treating neurodegenerative disease (claimed), enhancing expression of A2 neuroprotective astrocytes in brain tissue, enhancing expression of a neurofilament in a neuronal axon, and inhibiting expression of microglia in brain tissue. The neurodegenerative disease is chosen from Alzheimer's disease or dementia. ADVANTAGE - None given. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: a system comprising (i) a cognitive recovery index measurement unit for measuring the cognitive resilience index, (ii) a three-dimensional fluorescence microscopy image processing unit for analyzing the distribution of brain cells and (iii) confocal microscopy image processing unit that analyzes the distribution of brain cells; and a pharmaceutical composition comprising graphene oxide as an active ingredient.